KYTHERA Biopharmaceuticals (FRA:KYT) Price-to-Tangible-Book : 13.42 (As of Apr. 27, 2024)

View and export this data going back to . Start your Free Trial

What is KYTHERA Biopharmaceuticals Price-to-Tangible-Book?

As of today (2024-04-27), KYTHERA Biopharmaceuticals's share price is €66.74. KYTHERA Biopharmaceuticals's Tangible Book per Share of Jun. 2015 for the quarter that ended in Jun. 2015 was €4.97. Hence, KYTHERA Biopharmaceuticals's Price to Tangible Book Ratio of today is 13.42.

The historical rank and industry rank for KYTHERA Biopharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:

FRA:KYT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 5.42 Med: 8.74 Max: 23.12
Current: 13.43

During the past 5 years, KYTHERA Biopharmaceuticals's highest Price to Tangible Book Ratio was 23.12. The lowest was 5.42. And the median was 8.74.

FRA:KYT's Price-to-Tangible-Book is not ranked
in the Drug Manufacturers industry.
Industry Median: 2.36 vs FRA:KYT: 13.43

A closely related ratio is called PB Ratio. As of today, KYTHERA Biopharmaceuticals's share price is €66.74. KYTHERA Biopharmaceuticals's Book Value per Sharefor the quarter that ended in Jun. 2015 was €4.97. Hence, KYTHERA Biopharmaceuticals's P/B Ratio of today is 13.42.

KYTHERA Biopharmaceuticals Price-to-Tangible-Book Historical Data

The historical data trend for KYTHERA Biopharmaceuticals's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KYTHERA Biopharmaceuticals Price-to-Tangible-Book Chart

KYTHERA Biopharmaceuticals Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Price-to-Tangible-Book

6.71

5.55

13.31

KYTHERA Biopharmaceuticals Quarterly Data
	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15
Price-to-Tangible-Book	Get a 7-Day Free Trial														8.77	9.54	13.31	-	-

Competitive Comparison of KYTHERA Biopharmaceuticals's Price-to-Tangible-Book

For the Drug Manufacturers - General subindustry, KYTHERA Biopharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

KYTHERA Biopharmaceuticals's Price-to-Tangible-Book Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, KYTHERA Biopharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where KYTHERA Biopharmaceuticals's Price-to-Tangible-Book falls into.

KYTHERA Biopharmaceuticals Price-to-Tangible-Book Calculation

KYTHERA Biopharmaceuticals's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Jun. 2015 )
	=	66.74	/	4.972
	=	13.42

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

KYTHERA Biopharmaceuticals Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of KYTHERA Biopharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

KYTHERA Biopharmaceuticals (FRA:KYT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » KYTHERA Biopharmaceuticals Inc (FRA:KYT) » Definitions » Price-to-Tangible-Book

Traded in Other Exchanges

N/A

Address

Website

http://www.kytherabiopharma.com

KYTHERA Biopharmaceuticals Inc was incorporated in Delaware in June 2004 under the name Dermion, Inc. It commenced operations in August 2005, and it changed its name to AESTHERx, Inc. In July 2006, it changed its name to KYTHERA Biopharmaceuticals, Inc. It is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. The Company's objective is to develop first-in-class, prescription aesthetic products using an approach that relies on the scientific rigor of biotechnology to address unmet needs in the rapidly-growing market for aesthetic medicine. The Company's initial focus is on the facial aesthetics market, which comprises the majority of the aesthetic medicine market. The Company's product candidate, ATX-101, is a potential first-in-class, injectable drug in late stage clinical development for the reduction of submental fat, which commonly presents as an undesirable double chin. Based on clinical trials conducted to date, ATX-101 has exhibited significant, meaningful and long-lasting results in the reduction of submental fat.

KYTHERA Biopharmaceuticals (FRA:KYT) Headlines

No Headlines